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The study of MSC trafficking is clinically relevant for minimally invasive cell therapy to promote regeneration
of damaged tissue, to treat inflammation, and to promote angiogenesis. However, these studies are
complicated by the diverse methods used to culture, characterize, and deliver MSCs and by the variety of
methods used to assess homing events. This review provides a critical analysis of the methods used to track
homing of exogenously infused MSCs and discusses strategies for enhancing their trafficking to particular
tissues.Introduction
Mesenchymal stem cells (MSCs), also referred to as connective
tissue progenitor cells or multipotent mesenchymal stromal cells
(Dominici et al., 2006), have demonstrated significant potential
for clinical use. This clinical utility is due to their convenient isola-
tion, their lack of significant immunogenicity permitting allogenic
transplantation without immunosuppressive drugs, their lack of
ethical controversy, and their potential to differentiate into
tissue-specific cell types (Sasaki et al., 2008; Toma et al.,
2002) with trophic activity (Zhang et al., 2007), to promote vascu-
larization (Martens et al., 2006), and to promote potent immuno-
suppressive effects (reviewed in Nauta and Fibbe, 2007). Thus,
MSCs have been the focus of a regime of emerging therapeutics
to regenerate damaged tissue and treat inflammation resulting
from cardiovascular disease and myocardial infarction (MI), brain
and spinal cord injury, cartilage and bone injury, Crohn’s
disease, and graft-versus-host disease (GVHD) during bone
marrow transplantation (Phinney and Prockop, 2007). Although
local transplantation or injection of MSCs represents a potential
approach that may be useful in certain settings (Bantubungi
et al., 2008; Petite et al., 2000), the potential for minimally inva-
sive delivery of MSCs via systemic infusion is of particular
interest (Lee et al., 2008; Sackstein et al., 2008; Wang et al.,
2008b). However, a significant barrier to the effective implemen-
tation of MSC therapy is the inability to target these cells to
tissues of interest with high efficiency and engraftment.
The study of MSC homing following mobilization of host
MSCs, or following systemic infusion of exogenous MSCs, is
extremely complex. The challenges facing these efforts are
due to a number of factors, including the lack of universally
accepted criteria for defining the MSC phenotype and their func-
tional properties, by the rare presence of MSCs within blood, and
by the diverse methods used to culture MSCs and study their
homing potential. Critical questions pertinent to all studies in
the MSC trafficking field include the following: (1) Can host
MSCs be mobilized into peripheral blood? (2) Can exogenously
delivered MSCs home to ischemic tissues or sites of inflamma-206 Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc.tion from peripheral blood, and what is the efficiency of this
process? And (3), can host MSCs be mobilized into peripheral
blood and then target ischemic tissues? The different routes
for MSC trafficking represented in these questions are illustrated
in Figure 1. The third question is the most technically difficult to
address and, hence, the least discussed in the current literature.
The first question has already been reviewed elsewhere (He
et al., 2007) and thus will only be briefly discussed.
This review will focus on providing a critical analysis of the
methods developed to track the homing of exogenously infused
MSCs. Pertinent considerations that will be emphasized include
(1) how MSCs are cultured, (2) methods used to deliver MSCs, (3)
potential mechanisms for MSC engraftment, (4) methods used to
quantify MSC homing, and (5) methods used to characterize the
MSCs following a homing event. We will also discuss strategies
that have been employed to enhance trafficking of MSCs to
particular tissues, and the hurdles hindering their translation to
the clinical setting.
Definition of MSCs and MSC Homing
MSCs may be defined as multipotent cells capable of self-
renewal that can give rise to a number of unique, differentiated
mesenchymal cell types (da Silva Meirelles et al., 2008). Despite
this definition, many researchers use different methods to
culture MSCs, assess their differentiation potential, and evaluate
their capacity for self-renewal. Although MSCs may be derived
from multiple tissues, it is critical to consider that significant
phenotypic differences in MSCs exist which may reflect distinct
functional properties (Bianco et al., 2008), and this heterogeneity
may be a function of their tissue microenvironment (da Silva
Meirelles et al., 2006). Also, it is critical to consider that MSCs
exhibit a striking similarity to vascular mural cells called pericytes
that are embedded within the vascular basement membrane of
microvessels and capillaries throughout the body (Crisan et al.,
2008; da Silva Meirelles et al., 2008).
Given the lack of universally accepted criteria for defining
a MSC, the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy (ISCT) proposed
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based scientific investigations and preclinical studies (Dominici
et al., 2006). As part of the minimal criteria, human MSCs must
adhere to tissue culture plastic; be positive for CD105, CD73,
and CD90 and negative for CD45, CD34, CD14 or CD11b,
CD79a, or CD19 and HLA-DR; and must be able to differentiate
to osteoblasts, adipocytes, and chondroblasts under standard
in vitro differentiating conditions. Given the heterogeneity of
typical MSC culture procedures and a lack of enforcement of
the above-mentioned characterization criteria, definitive conclu-
sions based on the literature are often difficult to surmise.
MSC homing is defined as the arrest of MSCs within the
vasculature of a tissue followed by transmigration across the
endothelium. Such a nonmechanistic definition is appropriate,
given the current absence of a definitive MSC homing mecha-
nism, unlike the well-characterized leukocyte adhesion cascade
that defines leukocyte homing. The lack of data describing
the exact positioning of the MSCs following infusion makes it
difficult to determine if the cells have arrested within the vessels
(localization) or have undergone transendothelial migration
(homing).
Can Host MSCs Be Mobilized into Peripheral Blood?
The potential for MSC trafficking under physiological steady-
state conditions is contentious, with reports in the literature of
diametrically opposed findings. Studies that support the pres-
ence of MSCs within blood have reported only minute quantities
of circulating MSCs (Kuznetsov et al., 2001), whereas several
studies report the inability to locate any circulating MSCs at all
(reviewed in He et al., 2007). The failure to harvest sufficient
numbers of circulating MSCs at steady-state conditions is
complicated by the need to access blood via venapuncture,
which in theory could release small quantities of pericytes or
Figure 1. The Active MSC Homing Circuit
MSCs play several roles (red text within pink
boxes) depending on their anatomic location.
Studies have shown their presence in both periph-
eral blood and healthy tissues and organs (listed in
gray), in addition to the bone marrow, from which
they have historically been isolated. Numerous
active homing routes exist for MSCs (arrows).
Red arrows represent paths that have been
substantiated by published studies. Sites of
inflammation include acute inflammation due to
injury, chronic inflammation (e.g., GvHD), and
tumors.
other connective tissue cells into the
circulation. Interestingly, da Silva Mer-
eilles et al. were consistently unable to
derive a long-term culture of MSCs from
portal vein-accessed blood, a technique
that reduced the possibility of pericyte
or other connective tissue cell contami-
nation of the blood sample (da Silva Meir-
elles et al., 2006). However, the success
of isolating MSCs is also likely depen-
dent on the methods of mobilizing
MSCs into peripheral blood, eliminating
contaminating cells, and methods of
culturing the isolated MSCs. It is important to note that MSCs
isolated from peripheral blood have shown heterogeneous
marker expression. Specifically, an early study isolated
adherent, fibroblast-like stem cells with osteogenic and adipo-
genic potential from the blood of four mammalian species
including human, which were distinguished from BM-derived
human MSCs by the absence of Stro-1 and endoglin (Kuznet-
sov et al., 2001). Other studies report the isolation of MSCs
from peripheral blood using preselection methods for CD133+
cells in G-CSF-mobilized peripheral blood (Tondreau et al.,
2005). These cells have potential to differentiate into adipo-
cytes, osteoblasts, chondrocytes, and neuronal/glial cells (Ro-
chefort et al., 2006).
Of particular significance, increased numbers of MSCs have
been isolated from peripheral blood cells of injured mice (to
induce intimal hyperplasia) compared to noninjured controls
(Wang et al., 2008a). This trend correlated with significant
increases in peripheral blood concentrations of the cytokines
VEGF and G-CSF. Moreover, MSCs from injured animals were
cultured up to ten passages and had trilineage differentiation
potential in vitro, compared to MSCs from noninjured animals,
which could only be passaged twice. These results need to be
repeated by several groups before a central dogma—that the
presence of circulating MSCs occurs only in response to
injury—can be developed.
Exogenously Delivered MSCs
Culturing of MSCs
There are several factors regarding the MSC culture conditions
that should be reported for homing experiments, as the culture
condition may have a significant impact on MSC function. For
example, the confluency of MSCs cultured under laboratory
conditions before being infused can affect their migrationCell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. 207
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transendothelial migration in MSCs by increasing the production
of a natural matrix metalloproteinase (MMP) inhibitor, TIMP-3 (De
Becker et al., 2007). The passage number of MSCs used is also
important, as MSCs have been shown to gain or lose certain
surface receptors during culture, which might influence their
homing capability. Freshly isolated MSCs have been shown to
display enhanced homing ability compared to their culture-
expanded counterparts (Rombouts and Ploemacher, 2003).
Homing receptors, such as CXCR4, a chemotactic receptor for
SDF-1 that is upregulated in the bone marrow and in ischemic
tissues, is usually absent on the surface of culture-expanded
MSCs (Phinney and Prockop, 2007; Ruster et al., 2006; Sack-
stein et al., 2008; Wynn et al., 2004). However, treating MSCs
with a cocktail of cytokines in culture has been shown to induce
high surface expression of CXCR4 that enhanced homing ability
(Shi et al., 2007). Given that the expression of CXCR4 and other
homing receptors is typically observed on a subset of MSCs and
often lost with culture expansion, it is plausible that these may be
naturally present on endogenous MSCs but lost after culture
(Wynn et al., 2004). Interestingly, simulating ischemic environ-
ments in culture, which some believe is representative of the
MSC niche, may also increase MSC motility. Hypoxic precondi-
tioning increased MSC migration through Matrigel by upregulat-
ing MMPs (Annabi et al., 2003) and on tissue culture plastic
(Rosova et al., 2008) compared to MSCs maintained in normoxic
environments. In addition to the passage number, confluency of
the passaged cells, site of isolation, and properties of the media
and incubation environment, it is critical to consider the hetero-
geneity in MSC surface receptor expression and resulting MSC
behavior that has been observed both within and between
studies (Jones et al., 2002; da Silva Meirelles et al., 2006; Sim-
mons and Torok-Storb, 1991; Sordi et al., 2005; Wynn et al.,
2004). Such variability of MSC properties emphasizes the impor-
tance of comprehensive characterization of MSCs within each
study. It is especially important to have an accurate assessment
of MSC properties prior to injection or implantation of MSCs into
the highly complex and varying microenvironments that exist
within the body.
Delivery of MSCs
For MSC trafficking experiments, the timing of delivery, number
of cells delivered, and site of MSC infusion may impact the
engraftment efficiency and the destination of exogenously deliv-
ered cells. Both higher numbers of infused MSCs and early
delivery of MSCs following an event causing ischemia (e.g.,
MCAO) have been shown to improve engraftment rates (Chen
et al., 2001). MSCs were found to engraft in the myocardium at
higher rates 1 day after MI as compared to 14 days after MI, sug-
gesting that MSCs engraft specifically in response to acute MI
(Schenk et al., 2007). Although it may be expected that higher
infused numbers of MSCs should result in higher numbers of
engrafted MSCs and better functional outcomes, there may be
a plateau beyond which additional delivered cells may not
improve the outcome. For example, in a rat model of brain injury,
although neurological function after the systemic infusion of
MSCs was improved for a dose of 1 3 106 cells, no additional
enhancement was observed when 3 3 106 MSCs were infused
(Wu et al., 2008). Studies that have attempted to optimize the
protocol for MSC delivery in terms of numbers and timing found208 Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc.that higher numbers of MSCs and MSCs delivered sooner after
presentation of ischemia resulted in higher engraftment rates,
though differences in the extent of functional outcome were
not apparent (Omori et al., 2008).
The site of MSC delivery may impact the route MSCs travel to
reach the target organ. Systemic administration can be achieved
by intravenous (IV) injection, intraperitoneal (IP) injection, intra-
arterial (IA) injection, or intracardiac (IC) injection. IV delivery is
the least invasive; however, IC and IA delivery have led to higher
engraftment rates than IV delivery in certain models of MI (Bar-
bash et al., 2003; Freyman et al., 2006). IA injection close to
the target site (extracranial right internal carotid artery) in a model
of brain injury was shown by MRI imaging of radiolabeled cells to
significantly enhance homing to the brain versus distant IV injec-
tion (femoral vein) (Walczak et al., 2008). IA injection may reduce
accumulation of MSCs within filtering organs such as the lung,
liver, or spleen that is often observed following IV delivery (Bar-
bash et al., 2003; Kraitchman et al., 2005; Sackstein et al.,
2008); however, IA may also lead to increased probability of
microvascular occlusions (Walczak et al., 2008), which is termed
‘‘passive entrapment.’’ Since IC and IA delivery bypasses the
initial uptake by the lungs, more MSCs are available to engraft
at the ischemic site. IP delivery is rarely used but has been
employed to deliver MSCs to murine fetuses in a mouse model
of muscular dystrophy, since IV delivery was deemed inappro-
priate for this application (Chan et al., 2007). Following birth,
the donor cells were found in both muscle and nonmuscle
organs. It is unknown why IV delivery resulted in the consistent
death of the fetuses. A final method of delivery is local infusion,
which entails injecting MSCs directly into the tissue of interest.
DiI-labeled MSCs intravenously transfused into baboons were
undetectable in limb muscles compared to detection of DiO-
labeled MSCs following direct injection into the muscle (Beggs
et al., 2006). However, local infusion is likely not clinically feasible
in many cases due to its potentially high degree of invasiveness
(e.g., into the heart or brain), and locally administered cells often
die before significantly contributing to the healing response due
to diffusion limitations of nutrients and oxygen (Muschler et al.,
2004).
The First E in MSC Engraftment: Efficacy
It is presumed that therapeutic efficacy of infused MSCs relies on
extravasation and engraftment of systemically infused MSCs
where they may exhibit local trophic or paracrine activity or
where MSCs may inhabit a tissue and release paracrine factors
into the vasculature for a systemic effect. However, few studies
have provided insight into the mechanisms of homing. Specifi-
cally, it is unclear if the MSCs actively home to tissues using
leukocyte-like cell-adhesion and transmigration mechanisms
(reviewed in Ley et al., 2007) or become passively entrapped in
small-diameter blood vessels. Instead of selectin and integrin-
mediated cell arrest on inflamed endothelium (Ley et al., 2007),
it is possible that MSCs become passively arrested in capillaries
or microvessels including arterioles and postcapillary venules
(Sackstein et al., 2008; Walczak et al., 2008) (refer to Figure 2).
Passive entrapment is likely a function of the cell’s size and over-
all deformability. The mode of arrest is thus of particular impor-
tance for MSCs, since they are known to enlarge during in vitro
cell culture (Chavakis et al., 2008). Expansion of cell numbers
in culture is a necessary step during MSC therapy; however,
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nonspecific tissues including the lung (Barbash et al., 2003;
Sackstein et al., 2008). Geometrical and mechanical entrapment
of cells has been previously described after systemic injection of
MSCs (Barbash et al., 2003; Sackstein et al., 2008) and after
injection of endothelial progenitor cells into the tumor microvas-
culature (Vajkoczy et al., 2003). Passive arrest may be distin-
guished from active arrest by the observation of an altered blood
flow (i.e., through blocking a vessel) (Walczak et al., 2008). Cells
that home via leukocyte adhesion mechanisms quickly flatten
and spread on the underlying vascular endothelium in prepara-
tion for transmigration (Diacovo et al., 1996), which reduces
the possibility for altered blood flow. Understanding the mecha-
nisms of passive and active arrest will likely be essential for
developing more-effective MSC delivery strategies.
Methods Used to Probe the Active Arrest of MSCs. There is
substantial evidence that infused MSCs have higher engraftment
efficiencies within sites of inflammation or injury. An interesting
study by Francois et al. examined this through subjecting mice
to total body irradiation (TBI) and in some cases in combination
with additional local irradiation within the abdominal area or hind
leg (Francois et al., 2006). The engraftment of systemically
infused MSCs was measured 15 days later, and engraftment
levels were found to be higher in mice subjected to TBI
compared to nonirradiated mice. TBI induced a 2.8-fold increase
on engraftment levels of MSCs in the brain, 3-fold in the heart,
2.5-fold in the liver, 2.6-fold in BM, and 1.7-fold in muscles, while
levels of engraftment in the lung were not affected. This pattern
suggests that MSCs engrafted in response to radiation damage
except in the lung, in which engraftment rates remained the
same with or without radiation. Presumably, this lack of change
is because their presence in the lung resulted from a passive
process. However, we cannot discount the possibility that in
addition to integrin upregulation, especially that of VCAM-1
(Mazo et al., 2002), irradiation or the induction of MI also leads
to local changes in microvessel diameter (i.e., constriction)
(Eder et al., 2004; Freas et al., 1989), affecting passive arrest
and thus explaining the accumulation of MSCs in inflamed
tissue.
The most significant evidence for active arrest of MSCs within
inflamed tissues is supported by methodology involving integrin
blocking (Ip et al., 2007) and knockout studies (Ruster et al.,
2006) that show a dependence on selectin and integrin interac-
tions. For example, Ip et al. showed that blocking the b1-integrin
on MSCs, a component of the adhesion molecule VLA-4 that
governs the arrest of leukocytes on activated endothelium,
reduced their engraftment in ischemic myocardium (Ip et al.,
2007). Furthermore, using P-selectin knockout mice, Ruster
et al. showed via intravital microscopy that fewer MSCs slowed
down in postcapillary venules compared to wild-type mice (Rus-
ter et al., 2006). These results suggest that the engraftment of
MSCs within target tissues depends on specific molecular inter-
actions prior to the transmigration step, rather than a nonspecific
passive steric phenomena. These molecular interactions can
readily be studied in vitro via standard leukocyte adhesion
assays.
Figure 2. Model for Passive versus Active
Homing
(A) There are two potential mechanisms for how
MSCs may decelerate within the vasculature
during the homing process. The large size of
MSCs and/or narrower capillaries may reduce
the cell velocity due to physical interactions
leading to passive entrapment (top cell). Alterna-
tively, MSCs that deform likely pass through capil-
laries to postcapillary venules similar to leukocyte
homing (von Andrian, 1997) can (1) tether and (2)
roll on activated vaculature at sites of inflamma-
tion, where a chemokine gradient (red gradient)
is established.
(B) During passive arrest, an altered blood flow
(arrows) may be observed. In contrast, during
active arrest, cells quickly flatten and spread on
the underlying endothelium, and blood flow is
virtually unchanged. Although ICAM-1 expression
on ECs has been implicated in active arrest of
MSCs, it is not known which ligands present on
MSCs interact with this receptor.
(C) After active arrest, MSCs may transmigrate,
but the fate of passively arrested MSCs is unclear.
The molecular interactions that regulate MSC
homing are listed in green. A third possibility for
MSC engraftment within inflammatory tissues
(data not shown) involves passive arrest within
the vasculature proximal to the site of inflamma-
tion, followed by transmigration in response to
a chemokine gradient in the surrounding tissue.
It is also possible that the physical properties of
culture-expanded MSCs (i.e., increased size)
reduce the cell velocity enough within postcapil-
lary venues to permit engagement of firm adhesion
receptors (negating the need for rolling receptors), thus leading to a proposed mechanism that incorporates both aspects of active and passive homing. VLA-1,
very late antigen-4; VCAM-1, vascular cell-adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; MMPs, matrix metalloproteinases; TIMPs, tissue
inhibitor of metalloproteinases.Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. 209
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thelial cells in vitro. Ruster et al. showed that MSCs bind to endo-
thelial cells in a P-selectin-dependent manner and that rolling
MSCs interact with VLA-4/VCAM-1 that promotes firm adhesion
on the endothelial cells (Ruster et al., 2006). However, the rolling
velocities reported were 100–500 mm/s at shear stresses of
0.1–1.0 dynes/cm2. To provide context, leukocyte rolling has
been typically observed to be less than 5 mm/s at shear stresses
up to 4 dynes/cm2 (Goetz et al., 1994; Ley et al., 2007). The
observation of high rolling velocities of MSCs is likely explained
by the lack of in vitro activation (e.g., by TNF-a) required to mimic
endothelium within inflamed or injured tissues, which promotes
the expression of cell-adhesion receptors that regulate cell roll-
ing and firm adhesion. Also, it is important to note that interacting
leukocytes are typically defined by velocities lower than 50% of
the free stream velocity (Hong et al., 2007). However, this study
used a more generous criterion; namely, cells traveling at less
than the free stream velocity were considered to be rolling.
Although velocities of MSCs traveling on activated endothelium
were not reported, experiments that examined retention of firmly
adherent MSCs under shear showed a significant increase in the
number of MSCs that remained adhered to endothelial cells after
activation with TNF-a at shear stresses between 0.1 and
2.0 dynes/cm2. Nevertheless, given the generous criteria for an
interacting cell, the implications of this study into the mecha-
nisms of MSC homing are limited. Clearly, studies that examine
MSCs rolling on activated endothelium, at velocities and shear
rates that are physiologically relevant, are essential to further
elucidate potential MSC homing mechanisms. A study by Segers
et al. examined the firm adhesion of MSC under static and
various shear stress conditions on activated endothelium
(Segers et al., 2006). Similar to the study by Ruster et al., this
study highlighted the dominant role of VLA-4 and VCAM-1 as
effectors of firm adhesion. Interestingly, firm adhesion
receptor/ligand interactions including the VLA-4/VCAM-1 axis
mediates rolling due to changes in their tertiary conformations
(Alon et al., 1995; Salas et al., 2002; Sigal et al., 2000). Similar
studies to elucidate the actual mechanisms of MSC arrest on
vasculature demands attention in the field of MSC trafficking.
Methods Used to Probe the Transmigration of MSCs. Very few
studies have examined the transmigration of MSCs. Steingen
reported that MSCs can transmigrate through nonactivated
endothelial monolayers via VCAM-1/VLA-4 interactions, but
rather than undergoing complete diapedesis, as is observed
for leukocytes, MSCs tended to integrate with the endothelial
layer, perhaps as embedded pericytes (Steingen et al., 2008).
The time course for transmigration was long compared to leuko-
cytes, which take 5–20 min (Ley et al., 2007)—specifically, the
endothelial monolayer resealed over the integrated MSCs after
240 min, leaving the MSCs beneath the monolayer. This devi-
ance from previously studied leukocyte transmigratory behavior
might have resulted from the use of nonactivated endothelium,
rather than a physiologic inability of MSCs to transmigrate.
Lymphocytes, for example, exhibit significantly reduced trans-
migratory activity on nonactivated endothelium due to the
absence of pertinent cell-surface adhesion molecules. Such
subtleties are important to consider when interpreting and
comparing results between studies. Results thus far suggest
that specific MSC-endothelium interactions regulate transmigra-210 Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc.tion, although further studies are required to examine this
phenomenon under conditions that mimic an active inflamma-
tory state.
Methods Used to Promote Chemotaxis of Systemically Infused
MSCs. In addition to adhesive interactions that mediate MSC
homing to specific sites, chemokines released from tissue or
endothelial cells may promote activation of adhesion ligands,
transendothelial migration, chemotaxis, and/or subsequent
retention in surrounding tissue (Belema-Bedada et al., 2008;
Hordijk, 2003; Ponte et al., 2007). For example, systemically
infused GFP-labeled MSCs that express the MCP-1 receptor
CCR2 on their surface were infused into transgenic mice with
MCP-1 specifically expressed in the myocardium. MCP-1 is typi-
cally expressed at sites of inflammation and thus represents
a model homing chemokine (Belema-Bedada et al., 2008).
GFP-positive cells were found in the myocardium at high
frequencies of 20 cells/microscopic field compared to none in
the hearts of control mice 7 and 14 days later. These frequencies
were also 20 times higher than those for GFP-positive cells found
in skeletal muscle, brain, and kidney as detected by immunoflu-
orescence, and approximately eight times higher as detected by
real-time polymerase chain reaction (real-time PCR) analysis of
whole organs for eGFP mRNA. Unfortunately, the number of
MSCs found in the lung was not reported, a likely destination
for infused MSCs (Kraitchman et al., 2005). It is possible that indi-
rect effects, rather than the interaction of MSCs with MCP-1 via
the CCR2 receptor, was responsible for difference in the distri-
bution. For example, MCP-1 is known to upregulate adhesion
molecules on the endothelial surface and increase endothelial
permeability (Stamatovic et al., 2003). Hence, MSCs were trans-
fected with a vector expressing a truncated version of FROUNT
(DN-Frount). FROUNT binds to CCR2, enabling CCR2-mediated
chemotaxis toward MCP-1, but not HGF, SDF-1, or VEGF. DN-
Frount competes with endogenous FROUNT for CCR2 binding
and acts as a dominant-negative effector of CCR2-mediated
chemotaxis. DN-Frount-transfected MSCs lacked the capability
to home to the hearts of the MCP-1 transgenic mice compared
with nontransfected MSCs. Hence, the direct interaction of
CCR2 with MCP-1 was crucial to the engraftment of MSCs in
ischemic heart tissue in this model. In a similar study, systemi-
cally administered MSCs detected in the myocardium doubled
after the expression of another inflammatory chemokine, MCP-
3 (a ligand for CCR2 and CCR1), was induced in the myocardium
compared to nontransfected controls (Schenk et al., 2007). This
study, unlike Belema-Bededa et al., did not present evidence
that the response was directly due to the interactions between
CCR2 or CCR1 and MCP-3.
Methods Used to Assess the Role of Enzymes inMSCHoming. In
addition to chemokines and adhesion molecules, invasive cells
often secrete enzymes that are essential for their migratory
activity. MSCs secrete proteases that regulate transmigration
and invasion of the basement membrane of endothelium and
degrade extracellular matrix (ECM) during chemotaxis. Both
blocking antibodies toward MMP2 and SiRNA knockdown of
MMP2 in MSCs reduce transendothelial migration in vitro (De
Becker et al., 2007). The role of MMP2, as well as MT1-MMP
and TIMP-2, in MSC invasion was further confirmed by Ries
et al., who also showed that chemotactic invasion of MSCs
through human ECM-coated transwell chambers could be
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regulation of MMP-2, MT1-MMP, and TIMP-2 via RNAi signifi-
cantly impaired the migration of MSCs by 72%, 75%, and
65%, respectively, when compared with control cells that had
received a non-target-directed siRNA. Steingen et al. also
perfused MSCs through isolated mouse hearts and detected
the presence of gelatinases at sites of MSC invasion through
in situ zymography (Steingen et al., 2008). Thus MSCs possess
the ability to break down endothelial basement membrane and
migrate toward chemotactic factors.
The substantial migratory properties of systemically infused
MSCs were also demonstrated in a recent study using a rat
model of middle cerebral artery occlusion (MCAO). Specifically,
Feridex-labeled human MSCs were directly infused into either
the ipsilateral or contralateral hemisphere of the injured brain
(Kim et al., 2008) and imaged via MRI once a week up to 10
weeks. Regardless of the site of infusion, MSCs were found to
migrate and localize in both the boundary and core of the
infarcted tissue. This result was confirmed by Prussian blue
staining and immunohistochemistry using a human nuclei-
specific antibody, in which cells positive for both stains were
exclusively found in the infarcted region. The time series imaging
that showed the gradual movement of the MSCs toward the site
of inflammation, in the case of contralateral infusion, supports
the notion that MSCs possess extensive migratory capabilities
within a tissue. Such capabilities are likely a function of their
responsiveness to chemotactic factors and production of
ECM-degrading enzymes.
The Second E in MSC Engraftment: Efficiency
Although it has been well established that systemically infused
MSCs localize within injured, inflamed, and cancerous tissues,
their efficiency of homing as a function of local tissue properties
is unclear, and the method of detection, method of quantifica-
tion, and timing of quantification can significantly impact the
result. MSCs are often detected in vivo using radioactive labeling
(Barbash et al., 2003; Freyman et al., 2006; Gao et al., 2001b;
Kraitchman et al., 2005), fluorescent labeling (Kawada et al.,
2004), transduction of MSCs with reporter genes (Barbash
et al., 2003; Devine et al., 2001), species mismatch (i.e., injection
of human MSCs into a rodent), and probing for sex mismatch
(i.e., injection of female cells into a male rodent) via specific
genes by fluorescent in situ hybridization (Jiang et al., 2006; Per-
eira et al., 1998) or real-time PCR (Belema-Bedada et al., 2008;
Kumar and Ponnazhagan, 2007). These tracking and assess-
ment methods have been used for models such as acute MI,
cerebral ischemic stroke (Chen et al., 2001), brain injury (Wu
et al., 2008), pulmonary fibrosis (Ortiz et al., 2003), intimal hyper-
plasia (Wang et al., 2008a), and chronic graft rejection (Wu et al.,
2003) and are described in Table S1, available online. The
different sensitivities between methods may account for some
of the variability that is often observed (Bensidhoum et al.,
2004; Kraitchman et al., 2005).
The quantification of homing efficiency within a target tissue is
typically assessed by one of two techniques: (1) quantification of
the relative level of radioactivity in excised tissues and organs
(Barbash et al., 2003) or (2) averaging the number of fluorescently
labeled cells present in a fixed number of microscopic fields per
tissue sample (Barbash et al., 2003; Jiang et al., 2006; Kawada
et al., 2004). Of particular interest is the capability for real-timein vivo tracking of MSCs rolling along the vascular endothelium
(Ruster et al., 2006) and diapedesis of MSCs through the endo-
thelium within specific tissues (Sackstein et al., 2008). The avail-
able methods for assessing MSC trafficking have shown that
systemically infused MSCs can (1) preferentially target, with
limited efficiency, inflammation, sites of injury, tumors, and
specific tissues such as the bone marrow (Belema-Bedada
et al., 2008; Devine et al., 2001; Sackstein et al., 2008), and (2)
nonspecifically distribute throughout various tissues and organs
(Devine et al., 2003) including the lung, liver, kidney, and spleen,
where a high percentage of infused cells are often observed
(Barbash et al., 2003; Kraitchman et al., 2005). However, the
methods used to assess MSC homing efficiency are often rela-
tive, comparing between the densities of engrafted MSCs in
experimental and control groups versus quantifying the total
number of MSCs which have homed to a particular tissue.
Furthermore, no robust positive controls for high homing effi-
ciencies exist. Emerging techniques for tracking MSCs, which
include labeling with super paramagnetic iron oxide nanopar-
ticles (Hsiao et al., 2007; Song and Ku, 2007) or quantum dots
(Shah et al., 2007), may enhance the assessment of MSC
homing, although the utility of these techniques requires further
analysis.
Methods for Imaging the Precise Location of MSCs as a Function
of Time. It is important to consider that systemically infused
MSCs may redistribute after their initial localization in tissues.
Using SPECT/CT imaging, Kraitchman et al. showed that the
initial concentration of MSCs in the lung posttransfusion
decreased after 24 hr, with a simultaneous increase in MSCs
found in the infarcted heart tissue (Kraitchman et al., 2005).
Gao et al. also found that MSCs gradually moved from the lung
to the liver, spleen, kidney, and bone marrow (Gao et al.,
2001a). This observation suggests that the amount of time
between transfusion and detection must be considered when
interpreting such studies, as the relative distribution among
tissues and organs will vary depending on when the detection
takes place. Also, at earlier time points (e.g., less than 24 hr), it
becomes especially important to distinguish the local position
of MSCs within the tissues with respect to blood vessels.
Presumably, MSCs that remain inside the vasculature of the
tissue in which they are detected cannot be assumed to have
engrafted until they have extravasated through the vessel wall.
It is critical to know if MSCs are transiently residing within vessels
in the tissue, passively entrapped in vasculature (Vajkoczy et al.,
2003), or have extravasated. Discriminating between these
options requires high-resolution imaging with relevant staining
for blood vessels and specific tissue structures, as is performed
in Charles Lin’s laboratory (Sackstein et al., 2008). One must also
be cautious and consider the possibility that the localization of
observed donor MSCs may be due to fusion with endogenous
cells (Spees et al., 2003).
Characterization of MSCs Postdelivery
Characterization of engrafted MSCs following systemic infusions
is a big unmet need in the field of MSC trafficking. Achieving
progress in this area would be useful to determine if these exog-
enous MSCs can form an ‘‘MSC niche’’ following engraftment. It
is important to consider that data generated during the 80 s
showed engraftment of donor stromal cells following human
bone marrow transplantation (Keating et al., 1982) but was laterCell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. 211
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setting, using sex-mismatched bone marrow T cell-depleted
allografts, a limited reconstitution of marrow mesenchymal cells
was demonstrated. Specifically, stromal layers containing
donor-type cells were observed in 14 out of 41 patients in one
study (Cilloni et al., 2000) and 4 out of 14 patients in another
study (Tanaka et al., 1994). (For a more detailed examination of
MSC engraftment following bone marrow transplantation,
please see Koc and Lazarus [2001], Rombouts and Ploemacher
[2003], and Svennilson [2005].) In another study of significant
interest, MSCs from eGFP transgenic mice were isolated from
the BM, expanded in vitro, and systemically infused into wild-
type mice (Belema-Bedada et al., 2008). eGFP-positive cells
were isolated from the BMs of the wild-type mice 3 and 6 months
later, expanded, and reinfused into an additional, secondary
recipient. Again, eGFP-positive cells could be isolated from the
BM of this third mouse and expanded, albeit at lower numbers.
Unfortunately, one limitation of the study was the lack of thor-
ough characterization of the MSCs after each isolation. Ideally,
labeled cells should have been isolated from the bone marrow
after infusion, cultured, and characterized as suggested by the
ISCT (Dominici et al., 2006). The stemness of the isolated
MSCs was confirmed by only assaying their ability to express
myocyte markers in response to appropriate inductive cues.
Therefore, it remains open to question whether the isolated cells
were indeed MSCs or differentiated progeny, and thus it is crit-
ical that future experiments include thorough characterization
of the MSC phenotype.
Given the lack of sufficient characterization methods of system-
ically infused MSCs following engraftment, it is unknown whether
they engraft in their native state or differentiate to replenish the
parenchymal and stromal cells at an ischemic site. Delineation
between MSCs and their differentiated progeny has been attemp-
ted by assaying for markers unique to mature cell types that MSCs
were expected to differentiate into based on the tissue of interest
(Chan et al., 2007; Wu et al., 2003; Zhang et al., 2008b). For
example, infused cells or their progeny havebeen found toexpress
dystrophin in a muscular dystrophy model (Chan et al., 2007),
cytokeratin in a model of intestinal epithelium irradiation damage
(Zhang et al., 2008b), and osteocalcin in a model of MSC homing
to healthy bone marrow (Sackstein et al., 2008). The current chal-
lenges associated with characterization of MSCs following
systemic infusion are a consequence of the combined complexity
of defining what an MSC is, with sensitive means for detection and
isolation of MSCs within an in vivo system.
Methods for Engineering of MSCs to Enhance
the Homing Response
Methods of improving the trafficking and engraftment of MSCs
and other cell types are a high priority for cellular therapies.
Although culture-expanded MSCs express certain cell-surface
receptors that mediate aspects of homing including VLA-4 (Rus-
ter et al., 2006) and certain chemokine receptors (Ponte et al.,
2007), they do not express PSGL-1(Sackstein et al., 2008) and
have low expression levels of other pertinent adhesion and che-
mokine receptors (e.g., CXCR4), which typically governs teth-
ering and rolling of circulating cells on activated vascular endo-
thelium. Retrovirus vectors encoding homing receptors such
as CXCR4 have been recently used to enhance homing and212 Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc.engraftment of HSCs and MSCs through increasing cell invasion
in response to SDF-1, the ligand for CXCR4, which is typically
present at inflammatory sites (Brenner et al., 2004; Cheng
et al., 2008; Zhang et al., 2008a). In one example, genetically
modified MSCs overexpressing CXCR4 on their surface homed
to ischemic myocardium following systemic administration and
enhanced postmyocardial infarction recovery of left ventricular
function in a rat model (Cheng et al., 2008). In another study,
the a4 subunit of the VLA-4-integrin was similarly upregulated
on MSCs using an adenovirus vector, found to successfully
dimerize with b1-integrin to form VLA-4 and increase the homing
of MSCs to the bone marrow by more than 10-fold as compared
to nontransduced MSCs (Kumar and Ponnazhagan, 2007). Inter-
estingly, the engraftment of MSCs in the lung simultaneously
decreased. An alternative approach to gene therapy, which
may present potential safety concerns, involves chemical engi-
neering of cell-surface glycans to initiate cell rolling (Sackstein
et al., 2008). A critical initial step in the cascade of events during
cell homing involves cell rolling, during which cells engage shear-
resistant, low-affinity interactions with vascular endothelial cells
(Butcher, 1991). Specifically, Sackstein and colleagues enzy-
matically engineered an E-selectin binding motif that is respon-
sible for hematopoietic stem cell homing onto the surface of
MSCs (Sackstein et al., 2008). Since E-selectin is highly
expressed in bone marrow, substantial bone marrow engraft-
ment of systemically administered MSCs was achieved along
with rare foci of osteoid juxtaposed to the endosteal surface. A
similar approach has been applied to improve engraftment of
cord blood-derived HSCs (Xia et al., 2004). However, these
methods require complex sugar chemistry, and the scope of
potential alterations is limited to modification of existing cell-
surface ligands. Another approach that could be applied to
MSCs involves the conjugation of antibodies to the cell surface
via bispecific antibodies (Lee et al., 2007) or palmitated protein
G or protein A, which permits cell-surface functionalization by
potentially any antibody bearing an accessible Fc region (Dennis
et al., 2004). However, it is unclear how targeting based on these
firm adhesion approaches (i.e., with antibodies) would compare
to approaches that promote cell rolling at the target site. We have
recently demonstrated that a robust MSC rolling response can
be induced on P-selectin substrates in vitro by chemically
attaching ligands to the surface of MSCs. The method, which
involves covalent attachment of biotin to the cell surface fol-
lowed by streptavidin and a biotinylated ligand, can be used to
attach potentially any adhesion ligand to the surface of any cell
type to enhance targeting to specific tissues following systemic
infusion (Sarkar et al., 2008). In addition, culture conditions may
be used to stimulate the expression of certain homing receptors,
such as CXCR4 (Chavakis et al., 2008; Potapova et al., 2008).
Taken together, these approaches provide significant potential
for enhancing the homing of MSCs to specific tissues.
Summary and Prospective
There are several clinical trials being performed worldwide to
examine the systemic administration of MSCs to treat a variety
of diseases and tissue defects. Despite the general excitement
about these trials and the promising results thus far, there is
a major lack of understanding of how MSCs target specific
tissues. This gap in our knowledge may be why current clinical
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Reviewdosing includes high numbers of cells that may range from 150
million to 300 million MSCs administered twice per week over
the course of 2 weeks (National Institutes of Health, 2008).
Furthermore, the balance between the beneficial effects from
locally engrafted MSCs versus systemic effects from secreted
paracrine factors that diffuse into target tissues is unclear.
Typical problems faced by those in the MSC trafficking field
and recommended actions are discussed in Figure 3.
Whether MSCs mobilize and home under steady-state condi-
tions remains a common topic of debate. Progress in this area
has been stifled by the difficulties in identifying and isolating
native MSCs; most studies utilize culture-expanded MSCs that
do not express many of the cell-adhesion or chemokine recep-
tors that are responsible for the homing of leukocytes and
Figure 3. Problems Faced in Field of MSC
Trafficking
Given the complexities involved in identifying
MSCs and tracking their position and the lack of
standardized methods for culturing and character-
izing them, new studies in this area should
consider the common problems/challenges that
are experienced and the available methods to
address them.
hematopoetic stem cells. Furthermore,
tracking of MSCs after local transplanta-
tion or systemic infusion has relied on
techniques that have inherent disadvan-
tages, including indirect methodology,
significant manipulation of the host
biology (e.g., bone marrow reconstitu-
tion), or use of an exogenous MSC
source.
Based on the knowledge derived from
existing studies, we can conclude the
following:
(1) There is mounting evidence that
host MSCs appear to mobilize in
response to inflammation or injury and
target specific tissues via active mecha-
nisms; however, more work is required
to substantiate this model, and the origin
and mechanisms of trafficking of the
mobilized MSCs remain unresolved.
(2) Systemically infused MSCs are
frequently observed insignificant concen-
trations within the bone marrow compart-
ment, or within an injury or inflammatory
site, and these cells have potential to
reduce inflammation and promote tissue
regeneration. However, the exact location
of the MSCs (within the vessel or tissue)
and their phenotype remain elusive, and
thus broad conclusions cannot be
substantiated regarding their engraftment
or mechanisms that mediate their func-
tional properties.
(3) Direct methods of assessing native
MSCs and their trafficking properties is
a big unmet need required to conclusively elucidate mechanisms
of MSC trafficking during physiological and pathological states.
Detection of infused MSCs that remain in an undifferentiated
state compared to their differentiated progeny also presents
a significant challenge.
(4) Homing of culture-expanded MSCs is inefficient compared
to leukocytes and HSCs, which apparently is due to a lack of rele-
vant cell-adhesion and chemokine receptors; however, engi-
neering strategies are available to enhance the homing response.
The increased size of MSCs likely promotes passive cell entrap-
ment and reduces the number of MSCs that reach the target site.
As our understanding of the mechanisms of MSC trafficking
grows, the ability to enhance homing to specific tissues through
engineered approaches should significantly reduce the numberCell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. 213
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provide better outcomes for patients. Accumulating evidence
suggests that MSCs have a significantly larger role in regulating
wound healing and inflammatory diseases than previously
thought. Given the systemic nature of many diseases and the
desire to have minimally invasive therapies, systemic infusion
of MSCs that can promote tissue regeneration and immunosup-
pressive effects represents an attractive therapeutic approach.
The number of potential therapeutic applications and their effi-
ciency and efficacy will continue to grow as the fundamental
biology that is responsible for the MSC regenerative properties
and homing responses continues to be elucidated.
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